Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Tumor Effects

Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment

Bone Marrow Transplantation volume 45, pages 177–180 (2010)Cite this article

Abstract

Remissions of haematological malignancies have been reported after allo-SCT, despite donor cell rejection, suggesting that sustained allogeneic engraftment is not mandatory to obtain a lasting anti-tumour effect. To evaluate the potential benefit from transient post-allo-SCT alloreactivity, we took advantage of the Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC) registry to colligate 14 patients with an efficient and long-lasting allogeneic (GVL) effect after allo-SCT for haematological malignancies, despite transient or absent engraftment. None received a second allogeneic graft after autologous recovery. The median duration of remission after autologous reconstitution was 118 (12−252) months. Although we cannot exclude the possibility that some patients were cured before allo-SCT, this retrospective analysis does strongly suggest that an efficient GVL effect can be observed without sustained donor engraftment, and that the transient presence of donor T cells might be sufficient to induce a powerful GVL effect.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  2. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987; 2: 175–178.

    Article  CAS  PubMed  Google Scholar 

  3. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D . Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995; 345: 1144–1146.

    Article  CAS  PubMed  Google Scholar 

  4. Collins Jr RH, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511–516.

    Article  PubMed  Google Scholar 

  5. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  6. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405–412.

    Article  CAS  PubMed  Google Scholar 

  7. Ballester OF, Fang T, Raptis A, Ballester G, Wilcox P, Hiemenz J et al. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma. Bone Marrow Transplant 2004; 34: 419–423.

    Article  CAS  PubMed  Google Scholar 

  8. Rondon G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 2008; 14: 859–866.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Dey BR, McAfee S, Colby C, Cieply K, Caron M, Saidman S et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005; 128: 351–359.

    Article  CAS  PubMed  Google Scholar 

  10. Fouillard L, Deconinck E, Tiberghien P, Deschaseaux ML, Solary E, Mugneret F et al. Prolonged remission and autologous recovery in two patients with chronic myelogenous leukemia after graft failure of allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998; 21: 943–946.

    Article  CAS  PubMed  Google Scholar 

  11. Maury S, Belhadj K, Chami I, Kuentz M, Cordonnier C, Bories D . Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population. Bone Marrow Transplant 2001; 28: 717–720.

    Article  CAS  PubMed  Google Scholar 

  12. Serrano J, Roman J, Castillejo JA, Sanchez J, Navarro JA, Martin C et al. Autologous reconstitution with BCR-ABL-negative haematopoiesis after T cell-depleted allogeneic BMT for CML. Bone Marrow Transplant 1998; 22: 599–601.

    Article  CAS  PubMed  Google Scholar 

  13. Wakui M, Okamoto S, Ishida A, Tanosaki R, Mori T, Kawai Y et al. Durable molecular remission in a patient with chronic myelogenous leukemia and host-derived hematopoiesis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18: 801–804.

    CAS  PubMed  Google Scholar 

  14. Brunstein CG, Hirsch BA, Miller JS, McGlennen RC, Verfaillie CM, McGlave PB et al. Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: extended remission preceding eventual relapse. Bone Marrow Transplant 2000; 26: 1173–1177.

    Article  CAS  PubMed  Google Scholar 

  15. van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, Verweij PJ, Khan PM et al. Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse. Blood 1994; 83: 3059–3067.

    CAS  PubMed  Google Scholar 

  16. Cesano A, Visonneau S, Jeglum KA, Owen J, Wilkinson K, Carner K et al. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res 1996; 56: 3021–3029.

    CAS  PubMed  Google Scholar 

  17. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436–442.

    Article  PubMed  Google Scholar 

  18. Lucas KG, Salzman D, Garcia A, Sun Q . Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004; 100: 1892–1901.

    Article  PubMed  Google Scholar 

  19. Sun Q, Burton R, Reddy V, Lucas KG . Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol 2002; 118: 799–808.

    Article  PubMed  Google Scholar 

  20. Kraus AB, Shaffer J, Toh HC, Preffer F, Dombkowski D, Saidman S et al. Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 2003; 31: 609–621.

    Article  PubMed  Google Scholar 

  21. Rubio MT, Kim YM, Sachs T, Mapara M, Zhao G, Sykes M . Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood 2003; 102: 2300–2307.

    Article  CAS  PubMed  Google Scholar 

  22. Rubio MT, Saito TI, Kattleman K, Zhao G, Buchli J, Sykes M . Mechanisms of the antitumor responses and host-versus-graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: a critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-gamma-producing CD8+ T cells. J Immunol 2005; 175: 665–676.

    Article  CAS  PubMed  Google Scholar 

  23. Rubio MT, Zhao G, Buchli J, Chittenden M, Sykes M, Rubio MT et al. Role of indirect allo- and autoreactivity in anti-tumor responses induced by recipient leukocyte infusions (RLI) in mixed chimeras prepared with nonmyeloablative conditioning. Clin Immunol 2006; 120: 33–44.

    Article  CAS  PubMed  Google Scholar 

  24. Montagna D, Maccario R, Locatelli F, Montini E, Pagani S, Bonetti F et al. Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood 2006; 108: 3843–3850.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d'Hématologie, Centre Hospitalier Universitaire Jean Minjoz, Besançon, France

    E Daguindau & E Deconinck

  2. Département d'Oncologie et Hématologie, Centre Hospitalier Universitaire, Strasbourg, France

    B Lioure

  3. Service d'Hématologie, Hôpital Necker, APHP, Paris, France

    A Buzyn

  4. Service d'Hématologie-Greffe, Hôpital Saint Louis, APHP, Paris, France

    M Robin

  5. Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France

    C Faucher

  6. Service d'Hématologie, Hôpital Henri-Mondor, APHP, Créteil, France

    M Kuentz

  7. Inserm, UMR 645, Université de Franche-Comté, Etablissement Français du Sang Bourgogne Franche-Comté, Besançon, France

    P Tiberghien & E Deconinck

Authors
  1. E Daguindau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Lioure
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Buzyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Faucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Kuentz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Tiberghien
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E Deconinck
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the SFGM-TC

Corresponding author

Correspondence to E Deconinck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Daguindau, E., Lioure, B., Buzyn, A. et al. Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment. Bone Marrow Transplant 45, 177–180 (2010). https://doi.org/10.1038/bmt.2009.96

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.96

Keywords

This article is cited by

Search

Advanced search

Quick links